Brokerages expect that DexCom, Inc. (NASDAQ:DXCM) will announce earnings of ($0.17) per share for the current quarter, Zacks reports. Ten analysts have made estimates for DexCom’s earnings, with the highest EPS estimate coming in at $0.18 and the lowest estimate coming in at ($0.60). DexCom reported earnings of ($0.32) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 46.9%. The business is expected to report its next quarterly earnings results on Wednesday, May 1st.
On average, analysts expect that DexCom will report full year earnings of $0.46 per share for the current year, with EPS estimates ranging from ($0.16) to $0.79. For the next year, analysts forecast that the business will post earnings of $0.94 per share, with EPS estimates ranging from $0.52 to $1.38. Zacks’ EPS averages are an average based on a survey of research analysts that cover DexCom.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.38. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business had revenue of $338.00 million for the quarter, compared to analysts’ expectations of $331.60 million. During the same period in the previous year, the business earned $0.10 earnings per share. The company’s revenue was up 52.9% on a year-over-year basis.
In other DexCom news, Director Steven R. Altman sold 2,500 shares of DexCom stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $117.04, for a total transaction of $292,600.00. Following the transaction, the director now owns 3,449 shares of the company’s stock, valued at approximately $403,670.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,566 shares of DexCom stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $142.83, for a total value of $4,651,401.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,679 shares of company stock worth $15,043,754. Corporate insiders own 1.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in DXCM. Private Advisor Group LLC purchased a new position in DexCom during the 3rd quarter valued at about $347,000. Cambridge Investment Research Advisors Inc. purchased a new position in DexCom during the 3rd quarter valued at about $602,000. Commonwealth Equity Services LLC grew its stake in DexCom by 87.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,589 shares of the medical device company’s stock valued at $656,000 after acquiring an additional 2,146 shares in the last quarter. SG Americas Securities LLC grew its stake in DexCom by 20.8% during the 3rd quarter. SG Americas Securities LLC now owns 7,605 shares of the medical device company’s stock valued at $1,088,000 after acquiring an additional 1,308 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in DexCom during the 3rd quarter valued at about $286,000. 97.87% of the stock is currently owned by institutional investors.
DexCom stock traded up $0.72 during midday trading on Wednesday, hitting $119.10. The company’s stock had a trading volume of 1,055,901 shares, compared to its average volume of 1,673,220. The company has a current ratio of 7.64, a quick ratio of 7.32 and a debt-to-equity ratio of 1.52. DexCom has a 12 month low of $69.51 and a 12 month high of $156.16. The stock has a market cap of $10.65 billion, a PE ratio of 397.00 and a beta of 0.78.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.